Aegis Comments on Ampio (AMPE) Following STEP Study Delay; Affrims at 'Buy'
Tweet Send to a Friend
Aegis Capital affirms its Buy rating and $16 target price on Ampio Pharma (Nasdaq: AMPE) after the company announced a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
